FFA
MCRB icon

Farther Finance Advisors’s Seres Therapeutics MCRB Stock Holding History

Farther Finance Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$138 – 4598
2025
Q1 		$138 Hold
10
– – ﹤0.01% 4023
2024
Q4 		$170 Hold
10
– – ﹤0.01% 3691
2024
Q3 		$193 Hold
10
– – ﹤0.01% 3660
2024
Q2 		$147 Buy
+10
New +$167 ﹤0.01% 3545
2024
Q1 		– Hold
0
– -$4 – 3673
2023
Q4 		– Hold
0
– – – 3533

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Farther Finance Advisors's MCRB Position: Q2 2025 in Review

Farther Finance Advisors sold out of Seres Therapeutics (MCRB) in Q2 2025, closing a stake of 10 shares — an estimated $138 sold.

Farther Finance Advisors first reported a position in MCRB in Q2 2024 and held it in 4 quarters. The position peaked at $193 in Q3 2024. 33 funds tracked by Wall St. Rank hold MCRB as of Q2 2025.

  • Farther Finance Advisors reported no remaining Seres Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Farther Finance Advisors sold 10 Seres Therapeutics shares in Q2 2025, an estimated $138.
  • Farther Finance Advisors first reported a position in Seres Therapeutics in Q2 2024 and held it in 4 quarters.
  • Farther Finance Advisors's Seres Therapeutics position peaked at $193 in Q3 2024.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2025.

Based on Farther Finance Advisors's 13F filing for Q2 2025, filed 11 Jul 2025.